Sarepta Therapeutics | SRPT - Selling And Administration Expenses

Stock Price
20.30
Daily Change
-0.12 -0.59%
Monthly
-14.60%
Yearly
-66.41%
Q2 Forecast
21.08

Sarepta Therapeutics reported $105.38M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.33B 419M Mar/2026
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025